PL1866324T3 - Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka - Google Patents

Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka

Info

Publication number
PL1866324T3
PL1866324T3 PL06710096T PL06710096T PL1866324T3 PL 1866324 T3 PL1866324 T3 PL 1866324T3 PL 06710096 T PL06710096 T PL 06710096T PL 06710096 T PL06710096 T PL 06710096T PL 1866324 T3 PL1866324 T3 PL 1866324T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Application number
PL06710096T
Other languages
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of PL1866324T3 publication Critical patent/PL1866324T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06710096T 2005-03-21 2006-03-16 Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka PL1866324T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
EP06710096A EP1866324B1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1866324T3 true PL1866324T3 (pl) 2010-12-31

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06710096T PL1866324T3 (pl) 2005-03-21 2006-03-16 Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka

Country Status (20)

Country Link
US (1) US8263575B2 (pl)
EP (1) EP1866324B1 (pl)
JP (2) JP5345381B2 (pl)
CN (2) CN101175763A (pl)
AT (1) ATE471334T1 (pl)
AU (1) AU2006226182C1 (pl)
BR (1) BRPI0609704B8 (pl)
CA (1) CA2602324C (pl)
CY (1) CY1111538T1 (pl)
DE (1) DE602006014949D1 (pl)
DK (1) DK1866324T3 (pl)
ES (1) ES2348741T3 (pl)
GB (1) GB0505781D0 (pl)
IL (1) IL186104A (pl)
MX (1) MX2007011666A (pl)
PL (1) PL1866324T3 (pl)
PT (1) PT1866324E (pl)
SI (1) SI1866324T1 (pl)
WO (1) WO2006100439A1 (pl)
ZA (1) ZA200709011B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
SG172921A1 (en) 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
US9351989B2 (en) 2010-12-29 2016-05-31 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
LT3447061T (lt) 2011-03-01 2022-01-25 NuCana plc Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
EA028871B1 (ru) 2012-11-16 2018-01-31 Юниверсити Колледж Кардифф Консалтантс Лимитед Способ получения химических соединений
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
US20170101431A1 (en) * 2014-05-28 2017-04-13 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
CA2962373C (en) 2014-11-28 2023-04-25 Nucana Biomed Limited 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
AU2016355429B2 (en) 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
ES2907874T3 (es) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE69534745T2 (de) * 1995-04-21 2006-10-05 University Of South Florida, Tampa Immunopotenzierende 5'-nucleotidase-resistente inosinmonophosphat-derivate und ihre verwendung
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
US6245750B1 (en) * 1998-01-23 2001-06-12 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
AU2002322325A1 (en) * 2001-06-22 2003-01-08 Emory University Beta-2'-or 3'-halonucleosides
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
EP1773355B1 (en) * 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート

Also Published As

Publication number Publication date
ZA200709011B (en) 2009-01-28
BRPI0609704B8 (pt) 2021-09-28
CY1111538T1 (el) 2015-08-05
CA2602324A1 (en) 2006-09-28
CA2602324C (en) 2015-02-24
DK1866324T3 (da) 2010-09-27
ATE471334T1 (de) 2010-07-15
EP1866324A1 (en) 2007-12-19
PT1866324E (pt) 2010-09-16
AU2006226182C1 (en) 2012-06-14
JP2013173786A (ja) 2013-09-05
SI1866324T1 (sl) 2010-10-29
IL186104A (en) 2013-06-27
JP2008533191A (ja) 2008-08-21
GB0505781D0 (en) 2005-04-27
AU2006226182B2 (en) 2011-09-01
AU2006226182A1 (en) 2006-09-28
DE602006014949D1 (de) 2010-07-29
US20090215715A1 (en) 2009-08-27
JP5345381B2 (ja) 2013-11-20
CN101175763A (zh) 2008-05-07
MX2007011666A (es) 2007-11-14
BRPI0609704A2 (pt) 2010-04-20
US8263575B2 (en) 2012-09-11
IL186104A0 (en) 2008-01-20
BRPI0609704B1 (pt) 2020-12-01
WO2006100439A1 (en) 2006-09-28
EP1866324B1 (en) 2010-06-16
ES2348741T3 (es) 2010-12-13
CN103936807A (zh) 2014-07-23
JP5863702B2 (ja) 2016-02-17

Similar Documents

Publication Publication Date Title
IL186104A0 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
SG164368A1 (en) Treatment of cancer
MY146112A (en) Long-term feed - cancer patient
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
TW200612918A (en) Lonidamine analogs
MX2010001821A (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
MX2009010899A (es) Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas.
TW200716141A (en) Compositions and methods for treatment for neoplasms
TW200737268A (en) Ion sources, systems and methods
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
TW200637522A (en) Skin treatment articles and methods
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MY147247A (en) Organic compounds and their uses
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
MY166063A (en) Intravenous antiviral treatments
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer